Interactive Brokers Group Inc. Class A Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Interactive Brokers Group Inc. Class A Common Stock trades at $87.14 (market cap $39.18B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Interactive Brokers Group Inc. Class A Common Stock is far larger — about 349.2× Inovio Pharmaceuticals Inc's market cap, and Interactive Brokers Group Inc. Class A Common Stock pays a 0.4% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Interactive Brokers Group Inc. Class A Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| IBKR | INO | |
|---|---|---|
Market Cap | $39.18B | $112.19M |
Volume | 2,996,599 | 3,201,278 |
Sector | Financials | Health |
52-Week High | $98.19 | $2.65 |
52-Week Low | $61.05 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $31.48B | $83.51M |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Interactive Brokers operates an electronic brokerage platform for trading stocks, options, futures, currencies, and other assets. It also provides clearing and custody services.
Read more on IBKR →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →